Drug intelligence / Profile preview

ASP3291

Development stage: Phase 2
Lead developer: Telsar Pharma
Modality: Cyclic Peptides → Modified Peptides → Peptides

Overview

ASP3291 is a cyclic peptide that acts as a melanocortin receptor agonist. It was initially developed by Astellas Pharma and later by Telsar Pharma for the treatment of mild-to-moderate active ulcerative colitis. The drug's development has been discontinued.

Other names: ASP3291ASP-3291ASP 3291

Targets

MC1R (Melanocortin Type 1 Receptor)

Beyond the preview

Go deeper on ASP3291.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP3291.

Explore the full profile